STOCK TITAN
  1. Home
  2. News
  3. ATOS

Atossa Therapeutics Inc - ATOS STOCK NEWS

Welcome to our dedicated news page for Atossa Therapeutics (Ticker: ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Atossa Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Atossa Therapeutics's position in the market.

News
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
Rhea-AI Summary
Atossa Therapeutics and Quantum Leap Healthcare Collaborative have initiated a new study to evaluate (Z)-endoxifen in combination with abemaciclib in women with ER+/HER2- breast cancer. The study will enroll approximately 20 women with newly diagnosed ER+/HER2- invasive breast cancer to receive the combination therapy prior to surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
clinical trial
-
News
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
Rhea-AI Summary
Atossa Therapeutics, Inc. (ATOS) CEO to Speak at Noble Capital Markets Healthcare Conference. Atossa is a clinical stage biopharmaceutical company focusing on breast cancer treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
conferences
-
News
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Rhea-AI Summary
Atossa Therapeutics (ATOS) announces positive safety and efficacy data from Phase 2 EVANGELINE trial for ER+/HER2- breast cancer treatment. The study shows significant reduction in Ki-67 levels, target lesion decreases, and promising clinical outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.14%
Tags
clinical trial
News
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) reported fully enrolling two Phase 2 studies with data expected in the second half of 2024. They also dosed the first patient in a new Phase 2 breast cancer prevention study and provided updates on ongoing trials. The company ended 2023 with $88.5 million in cash and no debt.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
earnings
-
News
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
Rhea-AI Summary
Atossa Therapeutics, Inc. (ATOS) announces successful 5-year treatment of pre-menopausal ER+ breast cancer patient with (Z)-endoxifen therapy. The patient remains cancer-free with no safety issues. (Z)-endoxifen shows promise in changing breast cancer treatment paradigm.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.16%
Tags
none
-
News
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
Rhea-AI Summary
Atossa Therapeutics, Inc. (ATOS) has regained compliance with Nasdaq's minimum closing bid price requirement, ensuring its listing on the stock exchange. The company focuses on developing innovative medicines for breast cancer using (Z)-endoxifen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
Rhea-AI Summary
Atossa Therapeutics, Inc. appoints Dr. Tessa Cigler to its board of directors, enhancing its expertise in breast cancer treatment. Dr. Cigler's background in medical oncology and clinical investigation brings valuable insights to Atossa's (Z)-endoxifen development program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.17%
Tags
management
-
News
Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting
Rhea-AI Summary
Atossa Therapeutics, Inc. (ATOS) announced the presentation of data from the 40mg PK run-in cohort of the Phase 2 EVANGELINE study at the AACR Annual Meeting. The study focuses on (Z)-endoxifen as a neoadjuvant treatment for premenopausal women with ER+ / HER2- breast cancer, aiming to improve treatment options. Dr. Steven Quay, Atossa’s CEO, expressed excitement about the potential impact of (Z)-endoxifen in transforming premenopausal women's cancer treatment. The presentation details were provided for the upcoming event in April 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.75%
Tags
clinical trial
-
News
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
Rhea-AI Summary
Atossa Therapeutics, Inc. (ATOS) doses first patient with SERM in RECAST DCIS study, a Phase 2 platform study for breast cancer treatment without surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
News
Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) has fully enrolled the (Z)-endoxifen arm of the Phase 2 I-SPY 2 clinical trial, evaluating it as a neoadjuvant treatment for newly diagnosed estrogen receptor-positive invasive breast cancer. The study aims to down-stage the tumor, improve tumor resectability, and reduce breast cancer recurrence. The company looks forward to seeing data from this study in the second half of 2024. The (Z)-endoxifen arm enrolled 20 patients as part of the I-SPY 2 Endocrine Optimization Pilot Protocol (EOP).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
clinical trial
Stock ATOS logo
Atossa Therapeutics Inc

Nasdaq:ATOS

ATOS Rankings

#3842 Ranked by Market Cap
#3974 Ranked by Stock Gains
N/A Ranked by Dividends

ATOS Stock Data

192.97M
117.48M
0.06%
12.98%
8.43%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Seattle

About ATOS

atossa therapeutics, inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the united states. the company's lead program is the development of endoxifen, an active metabolite of tamoxifen which is in phase ii studies to treat and prevent breast cancer. it is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and chimeric antigen receptor t-cell therapies, directly to the site of breast cancer. the company was formerly known as atossa genetics inc. and changed its name to atossa therapeutics, inc. in january 2020. atossa therapeutics, inc. was founded in 2009 and is headquartered in seattle, washington.